Sagimet Biosciences Inc.

SGMTReported to SECin USCIK 0001400118Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 13. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 13
Form 4 lines at Sagimet Biosciences Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Kemble George—Option exercisenothing paid24,369 sharesAug 17, 2026Kemble Georgenothing paidExercise · Aug 17Option exercise24,369Aug 17, 2026
Kemble George—Option exercisenothing paid326,618 sharesAug 17, 2026Kemble Georgenothing paidExercise · Aug 17Option exercise326,618Aug 17, 2026
Kemble George—Open-market sell$3,591,580350,987 sharesAug 17, 2026Kemble George$3,591,580Sell · Aug 17Open-market sell350,987Aug 17, 2026
Kemble George—Option exercise$154,98724,369 sharesAug 17, 2026Kemble George$154,987Exercise · Aug 17Option exercise24,369Aug 17, 2026
Kemble George—Option exercise$2,077,290326,618 sharesAug 17, 2026Kemble George$2,077,290Exercise · Aug 17Option exercise326,618Aug 17, 2026